BCL2 and neoplasm: Venetoclax, a selective small‐molecule BCL‐2 inhibitor that binds directly to the BH3 domain of the BCL‐2 family protein, stimulates changes in mitochondrial outer membrane permeability and caspase activation to achieve rapid apoptosis of tumor cells [10].